Wilate
STN: BL 125251
Proper Name: von Willebrand Factor/Coagulation Factor VIII Complex (Human)
Tradename: Wilate
Manufacturer: Octapharma Pharmazeutika Produktionsges.m.b.H., License #1646
Indication:
WILATE is indicated in children and adults with von Willebrand disease for:
- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding
WILATE is indicated in adolescents and adults with hemophilia A for:
- Routine prophylaxis to reduce the frequency of bleeding episodes
- On-demand treatment and control of bleeding episodes
Product Information
Supporting Documents
- Clinical Pharmacology Supplement Review STN 125251/244- Wilate
- Statistical Review Memo STN 125251/244 - Wilate
- Clinical Review STN 125251/244 - Wilate
- September 25, 2019 Approval Letter - Wilate
- Statistical Review - Wilate
- Clinical Review - Wilate
- Approval History, Letters, Reviews, and Related Documents - Wilate
- Supporting Documents older than three years - Wilate